Spots Global Cancer Trial Database for graft vs host disease
Every month we try and update this database with for graft vs host disease cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Peripheral Blood Stem Cell Transplantation From Family Haploidentical Donors in Patients With Myelodysplastic Syndrome and Acute Leukemia Under Primary Prophylaxis With Posaconazole | NCT03434704 | Transplant-Rela... Leukemia, Acute Myelodysplastic... Graft Vs Host D... Fungal Infectio... | Conditioning tr... PBSC graft GvHD prophylaxi... Primary antifun... | 18 Years - | IRCCS San Raffaele | |
| Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation | NCT03842696 | Hematologic Dis... Acute Leukemia ... Chronic Myeloge... Chronic Myeloge... Chronic Myeloge... Myelodysplastic... Mantle Cell Lym... Follicular Lymp... Diffuse Large B... Non Hodgkin Lym... Graft Vs Host D... Graft-versus-ho... | Vorinostat Blood and Marro... Tacrolimus (or ... Methotrexate Mycophenolate M... Cyclophosphamid... | 3 Years - 39 Years | University of Michigan Rogel Cancer Center | |
| Sirolimus/Tacrolimus Combination After HLA Matched Related Peripheral Blood Stem Cell Transplants | NCT01488253 | Acute Leukemia ... Myelodysplastic... Leukemia, Myelo... Leukemia, Myelo... | Sirolimus Tacrolimus | 20 Years - 60 Years | The Korean Society of Blood and Marrow Transplantation | |
| Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplant | NCT00810602 | Hematologic Mal... Graft vs Host D... | reduced intensi... tacrolimus (sta... mycophenolate (... vorinostat | 18 Years - | University of Michigan Rogel Cancer Center | |
| CD34+ Enriched Transplants to Treat Myelodysplastic Syndrome | NCT05617625 | Myelodysplastic... Graft Vs Host D... Graft-versus-ho... | Busulfan Melphalan Fludarabine CliniMACS CD34+... | 18 Years - 75 Years | Baptist Health South Florida | |
| Haplo Peripheral Blood Sct In GVHD Prevention | NCT04473911 | GVHD AML ALL MDS MPN CMML Hodgkin Lymphom... Non Hodgkin Lym... Blood Stem Cell... Graft Vs Host D... Acute Myeloid L... Acute Lymphobla... Myelodysplastic... Myeloproliferat... Chronic Myelomo... Chemosensitive ... | FLUDARABINE CYCLOPHOSPHAMID... TBI Melphalan Sirolimus Mycophenolate m... RGI-2001 CYCLOPHOSPHAMID... | 18 Years - 80 Years | Massachusetts General Hospital | |
| Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS | NCT00025662 | Graft vs Host D... Myelodysplastic... Leukemia Leukemia, Myelo... Leukemia, Myelo... Leukemia, Lymph... Lymphoma Lymphoma, Mantl... Lymphoma, Non-H... Hodgkin Disease | RFT5-SMPT-dgA Isolex system | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants | NCT00001830 | Chronic Lymphoc... Graft vs Host D... Hodgkin's Disea... Multiple Myelom... Non Hodgkin's L... | Th2 cells in al... Th2 Cells | 12 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| MORPHEE : Mechanisms of Cell Death Induced by Extracorporeal Photochemotherapy | NCT05333367 | Cutaneous T-Cel... Graft Vs Host D... Graft Rejection | Samples collect... | 18 Years - 85 Years | Centre Hospitalier Universitaire de Besancon | |
| Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS | NCT00025662 | Graft vs Host D... Myelodysplastic... Leukemia Leukemia, Myelo... Leukemia, Myelo... Leukemia, Lymph... Lymphoma Lymphoma, Mantl... Lymphoma, Non-H... Hodgkin Disease | RFT5-SMPT-dgA Isolex system | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Active Immunization of Sibling Bone Marrow Transplant Donors Against Purified Myeloma Protein of the Recipient Undergoing Allogeneic Bone Marrow Transplantation | NCT00001561 | Graft vs Host D... Multiple Myelom... | Myeloma Immunog... GM-CSF | 18 Years - 60 Years | National Institutes of Health Clinical Center (CC) | |
| GVH 022P: Study Using Anti Tumor Necrosis Factor Antibody (Infliximab) for Treatment of Acute Graft Versus Host Disease | NCT00228839 | Graft vs Host D... | Infliximab | - 18 Years | Emory University | |
| Haplo Peripheral Blood Sct In GVHD Prevention | NCT04473911 | GVHD AML ALL MDS MPN CMML Hodgkin Lymphom... Non Hodgkin Lym... Blood Stem Cell... Graft Vs Host D... Acute Myeloid L... Acute Lymphobla... Myelodysplastic... Myeloproliferat... Chronic Myelomo... Chemosensitive ... | FLUDARABINE CYCLOPHOSPHAMID... TBI Melphalan Sirolimus Mycophenolate m... RGI-2001 CYCLOPHOSPHAMID... | 18 Years - 80 Years | Massachusetts General Hospital | |
| GVHD Prophylaxis With Methotrexate in Haploidentical HCT Using Posttransplant Cyclophosphamide | NCT04622956 | Graft Vs Host D... Hematopoietic N... | Methotrexate In... | 18 Years - 70 Years | University of Sao Paulo General Hospital | |
| Characteristics and Dynamics of TCR Repertoire in Patients With Hematological Malignancies After Allo-HSCT | NCT03575767 | Hematologic Neo... Hematopoietic S... Graft Vs Host D... Recurrence | Myeloablative H... | 12 Years - 55 Years | Affiliated Hospital to Academy of Military Medical Sciences | |
| CD34+ Enriched Transplants to Treat Myelodysplastic Syndrome | NCT05617625 | Myelodysplastic... Graft Vs Host D... Graft-versus-ho... | Busulfan Melphalan Fludarabine CliniMACS CD34+... | 18 Years - 75 Years | Baptist Health South Florida | |
| TCRαβ/CD19 Depletion of Stem Cell Grafts for Transplant | NCT05968170 | Graft Vs Host D... Graft-versus-ho... Acute Myeloid L... Acute Lymphobla... Non-hematologic... Hematologic Mal... | CliniMACS® devi... | - 21 Years | Children's Hospital Los Angeles | |
| Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors | NCT00679536 | Leukemia | Busulfan Fludarabine Thymoglobulin Total Body Irra... | - 21 Years | Ann & Robert H Lurie Children's Hospital of Chicago | |
| GVH 022P: Study Using Anti Tumor Necrosis Factor Antibody (Infliximab) for Treatment of Acute Graft Versus Host Disease | NCT00228839 | Graft vs Host D... | Infliximab | - 18 Years | Emory University | |
| HLA-Mismatched Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematological Malignancies | NCT00001748 | Graft vs Host D... Hematologic Neo... Lymphoma Myelodysplastic... Myeloid Leukemi... | Peripheral bloo... | - | National Institutes of Health Clinical Center (CC) | |
| Peg Interferon α-2b for Relapsed Hematological Malignancies After Allo-HSCT | NCT02634294 | Hematological N... Recurrence | Peg interferon ... | 14 Years - 60 Years | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | |
| Peripheral Blood Stem Cell Transplantation From Family Haploidentical Donors in Patients With Myelodysplastic Syndrome and Acute Leukemia Under Primary Prophylaxis With Posaconazole | NCT03434704 | Transplant-Rela... Leukemia, Acute Myelodysplastic... Graft Vs Host D... Fungal Infectio... | Conditioning tr... PBSC graft GvHD prophylaxi... Primary antifun... | 18 Years - | IRCCS San Raffaele | |
| Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors | NCT00679536 | Leukemia | Busulfan Fludarabine Thymoglobulin Total Body Irra... | - 21 Years | Ann & Robert H Lurie Children's Hospital of Chicago | |
| Abatacept as GVHD Prophylaxis Phase 2 | NCT01743131 | Graft vs Host D... Malignancy | Abatacept placebo | 6 Years - | Boston Children's Hospital | |
| IS-free Treg HaploHCT | NCT04678401 | Stem Cell Trans... Graft Vs Host D... Myeloid Leukemi... Myeloid Leukemi... Myelodysplastic... | Radiation Fludarabine Thiotepa Cyclophosphamid... Mesna Treg-enriched d... Unmodified dono... CD34+ Haplo Per... | 18 Years - 65 Years | Dana-Farber Cancer Institute | |
| IS-free Treg HaploHCT | NCT04678401 | Stem Cell Trans... Graft Vs Host D... Myeloid Leukemi... Myeloid Leukemi... Myelodysplastic... | Radiation Fludarabine Thiotepa Cyclophosphamid... Mesna Treg-enriched d... Unmodified dono... CD34+ Haplo Per... | 18 Years - 65 Years | Dana-Farber Cancer Institute | |
| Blood and Marrow Transplant Clinical Research Network | NCT00023530 | Bone Marrow Tra... Blood Disease Hematopoietic S... Leukemia Multiple Myelom... Myelodysplastic... Graft vs Host D... | fluconazole voriconazole bone marrow tra... thalidomide dexamethasone | 2 Years - | National Heart, Lung, and Blood Institute (NHLBI) | |
| The Role of Cyclosporine in Blood Cell Transplants With T-Cell Add-Back for Blood Cancers | NCT00001873 | Chronic Lymphoc... Graft vs Host D... Hematologic Neo... Multiple Myelom... Myelodysplastic... | Isolex 300i plu... | 10 Years - 55 Years | National Institutes of Health Clinical Center (CC) | |
| Blood and Marrow Transplant Clinical Research Network | NCT00023530 | Bone Marrow Tra... Blood Disease Hematopoietic S... Leukemia Multiple Myelom... Myelodysplastic... Graft vs Host D... | fluconazole voriconazole bone marrow tra... thalidomide dexamethasone | 2 Years - | National Heart, Lung, and Blood Institute (NHLBI) | |
| MORPHEE : Mechanisms of Cell Death Induced by Extracorporeal Photochemotherapy | NCT05333367 | Cutaneous T-Cel... Graft Vs Host D... Graft Rejection | Samples collect... | 18 Years - 85 Years | Centre Hospitalier Universitaire de Besancon | |
| MORPHEE : Mechanisms of Cell Death Induced by Extracorporeal Photochemotherapy | NCT05333367 | Cutaneous T-Cel... Graft Vs Host D... Graft Rejection | Samples collect... | 18 Years - 85 Years | Centre Hospitalier Universitaire de Besancon | |
| Potential of Transplanted Stem Cells to Mature Into Salivary Gland and Cheek Cells | NCT00023491 | Graft vs Host D... Sjogren's Syndr... | - | National Institutes of Health Clinical Center (CC) | ||
| Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants | NCT00001830 | Chronic Lymphoc... Graft vs Host D... Hodgkin's Disea... Multiple Myelom... Non Hodgkin's L... | Th2 cells in al... Th2 Cells | 12 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| IRENE-G Study: Impact of Resistance Exercise and Nutritional Endorsement on GvHD Symptoms | NCT05111834 | Graft Vs Host D... | Supervised resi... Nutritional end... | 18 Years - | University Hospital Heidelberg | |
| Bone Marrow Transplant Studies for Safe and Effective Treatment of Leukemia | NCT00001623 | Graft vs Host D... Hematologic Neo... Leukemia Multiple Myelom... Myelodysplastic... | Allogeneic Bone... | 10 Years - 55 Years | National Institutes of Health Clinical Center (CC) | |
| Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation | NCT03842696 | Hematologic Dis... Acute Leukemia ... Chronic Myeloge... Chronic Myeloge... Chronic Myeloge... Myelodysplastic... Mantle Cell Lym... Follicular Lymp... Diffuse Large B... Non Hodgkin Lym... Graft Vs Host D... Graft-versus-ho... | Vorinostat Blood and Marro... Tacrolimus (or ... Methotrexate Mycophenolate M... Cyclophosphamid... | 3 Years - 39 Years | University of Michigan Rogel Cancer Center | |
| Combined Bone Marrow and Kidney Transplant for Multiple Myeloma With Kidney Failure | NCT00062621 | Kidney Failure,... Multiple Myelom... | Combined bone m... | 18 Years - 65 Years | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Feasibility and Efficacy of Modified Donor Lymphocytes Infusion (CD45RA Negative Selected) After Haploidentical Transplantation With Post-transplantation Cyclophosphamide in Patients With Hematological Malignancies (ONC-2016-002). | NCT04687982 | Bone Marrow Tra... Bone Marrow Tra... Graft Vs Host D... Infection Hematological M... | modified donor ... | 18 Years - | Istituto Clinico Humanitas | |
| Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. | NCT03229200 | Lymphoma, B-Cel... Lymphoma, Non-H... Leukemia, B-cel... Graft Vs Host D... Solid Tumor | Ibrutinib | 18 Years - | Pharmacyclics Switzerland GmbH | |
| IS-free Treg HaploHCT | NCT04678401 | Stem Cell Trans... Graft Vs Host D... Myeloid Leukemi... Myeloid Leukemi... Myelodysplastic... | Radiation Fludarabine Thiotepa Cyclophosphamid... Mesna Treg-enriched d... Unmodified dono... CD34+ Haplo Per... | 18 Years - 65 Years | Dana-Farber Cancer Institute | |
| GVH 022P: Study Using Anti Tumor Necrosis Factor Antibody (Infliximab) for Treatment of Acute Graft Versus Host Disease | NCT00228839 | Graft vs Host D... | Infliximab | - 18 Years | Emory University | |
| IRENE-G Study: Impact of Resistance Exercise and Nutritional Endorsement on GvHD Symptoms | NCT05111834 | Graft Vs Host D... | Supervised resi... Nutritional end... | 18 Years - | University Hospital Heidelberg | |
| oGVHD After Bone Marrow Transplantation: a Territory-wide Cohort | NCT05170347 | Graft Vs Host D... Haematological ... Cancer | 18 Years - | The University of Hong Kong |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
